Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Lowrie has played Sherlock Holmes in the radio drama series The Further Adventures of Sherlock Holmes on the program Imagination Theatre since 2001. He also voiced Holmes in the program's related radio series The Classic Adventures of Sherlock Holmes. He and Lawrence Albert, who voices Dr. Watson on the program, are the longest-running audio Holmes and Watson team in American radio history. In 2011, he published a science fiction novel titled Dancing with Eternity. An audiobook version narrated by Lowrie and McLain was released in April 2014. In 2021, Lowrie directed a livestreamed version of the play 'night, Mother starring his wife Ellen McLain and Sheila Houlahan on the online platform Twitch with the story adapted by McLain within the context of the COVID-19 pandemic. The filmed online play is performed through an online face-to-face chat with the screen split between McLain's and Houlahan's screens, occasionally interrupted by cuts to pre-filmed footage relevant to the story. Lowrie has also had small roles in several live-action films, most notable of which being the 2025 critically acclaimed period drama Train Dreams as a foreman overlooking the construction of a railroad for the Spokane International Railway (credited as Mr. Sears).
==== Reaction with compounds containing active methylene groups ==== In the presence of alkoxides, reactions of ethylene oxide with compounds containing active methylene group leads to the formation of butyrolactones:
Diski was a regular contributor to the London Review of Books; the collections Don't and Why Didn't You Do What You Were Told? collect articles and essays written for the publication. Her memoirs include In Gratitude, The Sixties, Skating to Antarctica, and Stranger on a Train: Daydreaming and Smoking around America With Interruptions, for which she won the 2003 Thomas Cook Travel Book Award. Benjamin Disraeli (1804–1881) novelist, poet, playwright, writer, and prime minister A prolific novelist, the 1840s Disraeli wrote a trilogy of novels with political themes. Coningsby attacks the evils of the Whig Reform Bill of 1832 and castigates the leaderless conservatives for not responding. Sybil; or, The Two Nations (1845) reveals Peel's betrayal over the Corn Laws. These themes are expanded in Tancred (1847). With Coningsby; or, The New Generation (1844). Isaac D'Israeli, (11 May 1766 – 19 January 1848) was a British writer, scholar and the father of British prime minister Benjamin Disraeli. He is best known for his essays and his associations with other men of letters. Michael Pinto-Duschinsky (born June 1943) Hungarian-born author, journalist, scholar, political consultant and writer. Anton Ehrenzweig (27 November 1908 – 5 December 1966) Austrian Jewish British author and theorist on modern art, psychoanalysis and Avant-garde music who wroteThe Psychoanalysis of Artistic Vision and Hearing (1953) and The Hidden Order of Art (1967).
=== Postnatal development === The postnatal population of dermal macrophages is achieved by the infiltration of circulating monocytes given proper CCR2 signalling, a pathway responding to chemokines. The infiltration of circulating monocytes can also be triggered through the upregulation of pro-inflammatory cytokines and chemicals such as sodium chloride. The infiltration of bone-marrow-derived monocytes generated postnatally creates a distinct population of dermal macrophages. They are LY6Chi monocytes, a type of circulating monocyte in the blood. The entry of LY6Chi monocytes to the dermis is CCR2-pathway-dependent. Their subsequent differentiation will create the postnatal population. The generation of dermal macrophages is highlighted by the expression of cell markers such as CD64, MERTK and the downregulation of CCR2.
Sources: en.wikipedia.org
=== 2011 recalls of Simvastatin and Toprol products === In June 2011, certain lots of Dr. Reddy's generic Simvastatin tablets were recalled due to tablets having a "musty" or "moldy" smell. On 24 June 2014, The New York Times published an article "Warning Unheeded, Heart Drugs Are Recalled" in which it said another large Indian manufacturer and "Dr. Reddy's Laboratories, have announced recalls over the past two months totalling more than 100,000 bottles" of "a widely used heart drug, Toprol XL" "because their products were not dissolving properly".
=== Physical properties === Vernix is a white viscous cream-like substance in appearance. The water is not uniformly distributed throughout, but rather exclusively present in the sponge-like corneocytes; despite its high water content, vernix is non-polar (due to lipids) and more vapor-permeable than stratum corneum.
== Pathophysiology == Pellagra can develop according to several mechanisms, classically as a result of niacin (vitamin B3) deficiency, which results in decreased nicotinamide adenine dinucleotide (NAD). Since NAD and its phosphorylated NADP form are cofactors required in many body processes, the pathological impact of pellagra is broad and results in death if not treated. The first mechanism is simple dietary lack of niacin. Second, it may result from deficiency of tryptophan, an essential amino acid found in meat, poultry, fish, eggs, and peanuts, which the body uses to make niacin. Third, it may be caused by excess leucine, as it inhibits quinolinate phosphoribosyl transferase (QPRT) and inhibits the formation of nicotinic acid to nicotinamide mononucleotide (NMN) causing pellagra-like symptoms to occur. Some conditions can prevent the absorption of dietary niacin or tryptophan and lead to pellagra. Inflammation of the jejunum or ileum can prevent nutrient absorption, leading to pellagra, and this can in turn be caused by Crohn's disease. Gastroenterostomy can also cause pellagra. Chronic alcoholism can also cause poor absorption, which combined with a diet already low in niacin and tryptophan produces pellagra. Hartnup disease is a genetic disorder that reduces tryptophan absorption, leading to pellagra. Alterations in protein metabolism may also produce pellagra-like symptoms.
Glycolipid transfer proteins Lipocalins including retinol binding proteins and fatty acid-binding proteins Polyisoprenoid-binding protein, such as YceI protein domain Ganglioside GM2 activator proteins CRAL-TRIO domain (α-Tocopherol and phosphatidylinositol sec14p transfer proteins) Sterol carrier proteins Phosphatidylinositol transfer proteins and STAR domains Oxysterol-binding protein
=== Other guidance === Because nanotechnology is a recent development, the health and safety effects of exposures to nanomaterials, and what levels of exposure may be acceptable, are subjects of ongoing research. Of the possible hazards, inhalation exposure appears to present the most concern. Animal studies indicate that carbon nanotubes and carbon nanofibers can cause pulmonary effects including inflammation, granulomas, and pulmonary fibrosis, which were of similar or greater potency when compared with other known fibrogenic materials such as silica, asbestos, and ultrafine carbon black. Acute inhalation exposure of healthy animals to biodegradable inorganic nanomaterials have not demonstrated significant toxicity effects. Although the extent to which animal data may predict clinically significant lung effects in workers is not known, the toxicity seen in the short-term animal studies indicate a need for protective action for workers exposed to these nanomaterials, although no reports of actual adverse health effects in workers using or producing these nanomaterials were known as of 2013. Additional concerns include skin contact and ingestion exposure, and dust explosion hazards. Elimination and substitution are the most desirable approaches to hazard control.
Sources: en.wikipedia.org
=== Archaea === Archaea have a single type of RNAP, responsible for the synthesis of all RNA. Archaeal RNAP is structurally and mechanistically similar to bacterial RNAP and eukaryotic nuclear RNAP I-V, and is especially closely structurally and mechanistically related to eukaryotic nuclear RNAP II. The history of the discovery of the archaeal RNA polymerase is quite recent. The first analysis of the RNAP of an archaeon was performed in 1971, when the RNAP from the extreme halophile Halobacterium cutirubrum was isolated and purified. Crystal structures of RNAPs from Sulfolobus solfataricus and Sulfolobus shibatae set the total number of identified archaeal subunits at thirteen. Archaea has the subunit corresponding to Eukaryotic Rpb1 split into two. There is no homolog to eukaryotic Rpb9 (POLR2I) in the S. shibatae complex, although TFS (TFIIS homolog) has been proposed as one based on similarity. There is an additional subunit dubbed Rpo13; together with Rpo5 it occupies a space filled by an insertion found in bacterial β′ subunits (1,377–1,420 in Taq). An earlier, lower-resolution study on S. solfataricus structure did not find Rpo13 and only assigned the space to Rpo5/Rpb5. Rpo3 is notable in that it's an iron–sulfur protein. RNAP I/III subunit AC40 found in some eukaryotes share similar sequences, but does not bind iron. This domain, in either case, serves a structural function. Archaeal RNAP subunit previously used an "RpoX" nomenclature where each subunit is assigned a letter in a way unrelated to any other systems.
Aortic dissection (AD) occurs when an injury to the innermost layer of the aorta allows blood to flow between the layers of the aortic wall, forcing the layers apart. In most cases, this is associated with a sudden onset of agonizing chest or back pain, often described as "tearing" in character. Vomiting, sweating, and lightheadedness may also occur. Damage to other organs may result from the decreased blood supply, such as stroke, lower extremity ischemia, or mesenteric ischemia. Aortic dissection can quickly lead to death from insufficient blood flow to the heart or complete rupture of the aorta. AD is more common in those with a history of high blood pressure; a number of connective tissue diseases that affect blood vessel wall strength including Marfan syndrome and Ehlers–Danlos syndrome; a bicuspid aortic valve; and previous heart surgery. Major trauma, smoking, cocaine use, pregnancy, a thoracic aortic aneurysm, inflammation of arteries, and abnormal lipid levels are also associated with an increased risk. The diagnosis is suspected based on symptoms with medical imaging, such as CT scan, MRI, or ultrasound used to confirm and further evaluate the dissection. The two main types are Stanford type A, which involves the first part of the aorta, and type B, which does not. Prevention is by blood pressure control and smoking cessation. Management of AD depends on the part of the aorta involved. Dissections that involve the first part of the aorta (adjacent to the heart) usually require surgery.
== Early life == There is limited information about her personal life and motivation for science. Daly's father, Ivan C. Daly, had immigrated from the British West Indies, found work as a postal clerk and eventually married Helen Page of Washington, D.C. They lived in New York City, and Daly was born and raised in Corona, Queens. She often visited her maternal grandparents in Washington, where she read about scientists and their achievements in her grandfather's extensive library. She was especially impressed by Paul de Kruif's The Microbe Hunters, a work which influenced her decision to become a scientist. Daly's interest in science was also influenced by her father, who had attended Cornell University with the intention of becoming a chemist, but had been unable to complete his education due to a lack of funds. Daly would thus complete her father's ambition by majoring in chemistry. Years later, she started a Queens College scholarship fund in his honor to assist minority students majoring in chemistry and or physics. Daly married and took the name Marie Maynard Daly Clark. Her husband died before her and they did have 2 children. She died on October 28, 2003.
20,000, 11 December 2007- On 29 October 2007, the SENSEX crossed the 20,000 mark for the first time with a massive 734.5-point gain, but closed below the 20,000 mark. The SENSEX would close above the 20,000 mark for the first time on 11 December 2007. It took 42 days after reaching the 19,000 milestone to close above 20,000 points for the first time. The journey of the last 10,000 points was covered in just 483 sessions, compared to 7,297 sessions taken to touch the 10,000 mark from its base value of 100 points. In the second half of 2007 alone, the SENSEX reached six 1,000-point milestones.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.